$COYA

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Compa

Coya Therapeutics (COYA) completed enrollment of 120 patients in its Phase 2/3 ALS trial for COYA 302. The company expects topline data in early Q2 2027. This milestone marks progress toward the first controlled efficacy readout for the treatment.

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100 th ) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302, the Company’s co

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended t

Coya Therapeutics, Inc. (COYA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835022 0001835022 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,

Coya Therapeutics, Inc. has entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market (ATM) stock offering program, allowing the company to sell up to $30,000,000 worth of common stock. Leerink Partners will act as the sales agent, receiving a 3.0% commission on gross proceeds, and the shares will be offered under an existing Form S-3 shelf registration statement. This program provides Coya with a flexible method to raise capital as needed.

Coya Therapeutics has announced the publication of a study in Brain Communications demonstrating regulatory T-cell (Treg) dysfunction and systemic inflammation in frontotemporal dementia (FTD) patients. The research, led by Dr. Alireza Faridar and Dr. Stanley Appel, found reduced Treg function and increased pro-inflammatory cytokines in FTD patients. These findings support the mechanistic rationale for Coya's COYA 302 therapy, which aims to enhance Treg function and reduce inflammation in FTD and other neurodegenerative diseases.

COYA 303 reduced LPS-induced pro-inflammatory cells and boosted anti-inflammatory Tregs in the brain and body. Significant neuroinflammation reduction seen in the cortex and hippocampus after COYA 303 treatment. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →

Q&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs

Is it a good or bad thing when a stock experiences a golden cross technical event?